Radiotherapy for extramedullary leukaemic manifestation (Chloroma)

Strahlenther Onkol. 2018 Feb;194(2):164-173. doi: 10.1007/s00066-017-1236-4. Epub 2017 Nov 16.

Abstract

Purpose: Extramedullary leukaemic disease (EMD, synonym chloroma) is a rare solid manifestation of myeloid leukaemia for which the value of radiotherapy (RT) as a treatment strategy remains controversial. The aim of this study is to analyse the effectiveness of various RT doses for EMD in the modern treatment era.

Materials and methods: Between January 2000 and June 2016, 20 patients with total of 45 lesions underwent RT for EMD at our institution.

Results: With a median radiation dose of 26 Gy (range 4-42 Gy), local remission could be achieved in 91% of patients (complete remission rate: 71%). The median duration of local control (DOLC) was 17 months (95% confidence interval [CI] 0.5-33) and the median overall survival (OS) after chloroma onset was 24 months (95% CI 11-38). No noticeable difference between high- and low-dose regimens has been observed (74% versus 68%; P = 0.5). In the multivariate analysis, only Eastern Cooperative Oncology Group (ECOG) score and bone marrow state during RT have proven to be determinant for durable local control and OS.

Conclusions: Low-dose RT (≤26 Gy) achieves good local control compared to high-dose regimes. Bone marrow state during RT and ECOG score during RT may play a crucial role, influencing both DOLC and OS.

Keywords: Chloroma; Hematologic diseases; Intensity-modulated radiotherapy; Leukemia; Survival.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Radiation
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Radiotherapy, Intensity-Modulated / methods*
  • Sarcoma, Myeloid / mortality
  • Sarcoma, Myeloid / radiotherapy*
  • Survival Rate
  • Treatment Outcome
  • Young Adult